223 related articles for article (PubMed ID: 23518148)
1. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
Schramm N; Englhart E; Schlemmer M; Hittinger M; Übleis C; Becker CR; Reiser MF; Berger F
Eur J Radiol; 2013 Jun; 82(6):951-8. PubMed ID: 23518148
[TBL] [Abstract][Full Text] [Related]
2. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib.
Dudeck O; Zeile M; Reichardt P; Pink D
Ann Oncol; 2011 Aug; 22(8):1828-33. PubMed ID: 21289369
[TBL] [Abstract][Full Text] [Related]
3. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
[TBL] [Abstract][Full Text] [Related]
4. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Shinagare AB; Jagannathan JP; Kurra V; Urban T; Manola J; Choy E; Demetri GD; George S; Ramaiya NH
Eur J Cancer; 2014 Mar; 50(5):981-6. PubMed ID: 24388774
[TBL] [Abstract][Full Text] [Related]
5. Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors.
Shinagare AB; Barysauskas CM; Braschi-Amirfarzan M; O'Neill AC; Catalano PJ; George S; Ramaiya NH
Clin Imaging; 2016; 40(5):880-4. PubMed ID: 27179958
[TBL] [Abstract][Full Text] [Related]
6. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
[TBL] [Abstract][Full Text] [Related]
7. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
[TBL] [Abstract][Full Text] [Related]
8. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
Mabille M; Vanel D; Albiter M; Le Cesne A; Bonvalot S; Le Péchoux C; Terrier P; Shapeero LG; Dromain C
Eur J Radiol; 2009 Feb; 69(2):204-8. PubMed ID: 19046841
[TBL] [Abstract][Full Text] [Related]
10. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
[TBL] [Abstract][Full Text] [Related]
11. We should desist using RECIST, at least in GIST.
Benjamin RS; Choi H; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Charnsangavej C
J Clin Oncol; 2007 May; 25(13):1760-4. PubMed ID: 17470866
[TBL] [Abstract][Full Text] [Related]
12. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
[TBL] [Abstract][Full Text] [Related]
13. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
Stacchiotti S; Collini P; Messina A; Morosi C; Barisella M; Bertulli R; Piovesan C; Dileo P; Torri V; Gronchi A; Casali PG
Radiology; 2009 May; 251(2):447-56. PubMed ID: 19261927
[TBL] [Abstract][Full Text] [Related]
14. Assessing treatment response of osteolytic lesions by manual volumetry, automatic segmentation, and RECIST in experimental bone metastases.
Bretschi M; Fränzle A; Merz M; Hillengass J; Semmler W; Bendl R; Bäuerle T
Acad Radiol; 2014 Sep; 21(9):1177-84. PubMed ID: 24998693
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
16. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
17. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
18. Size determination and response assessment of liver metastases with computed tomography--comparison of RECIST and volumetric algorithms.
Rothe JH; Grieser C; Lehmkuhl L; Schnapauff D; Fernandez CP; Maurer MH; Mussler A; Hamm B; Denecke T; Steffen IG
Eur J Radiol; 2013 Nov; 82(11):1831-9. PubMed ID: 22717124
[TBL] [Abstract][Full Text] [Related]
19. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
20. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]